PTC Therapeutics Appoints Biotech Banking Veteran Jessica Chutter to Board
PTCT sits 80% above its 52-week low of $35.95.
Summary
PTC Therapeutics has appointed Jessica Chutter, a former Vice Chair of Healthcare Investment Banking at Morgan Stanley with over 40 years of experience, to its Board of Directors.
Key Events · Executive and Board Changes · PTCT
-
New Director Appointed
Jessica Chutter, a veteran of healthcare investment banking at Morgan Stanley, was appointed to the Board of Directors, effective March 24, 2026.
-
Extensive Industry Experience
Ms. Chutter brings over 40 years of experience, including serving as Vice Chair of Healthcare Investment Banking and Chair of Biotechnology Investment Banking at Morgan Stanley, where she was involved in approximately $80 billion in capital raising and $85 billion in strategic transactions.
-
Strategic Board Enhancement
Her expertise is expected to be integral in charting the company's next stage of growth, leveraging her background in capital markets and M&A.
Analysis · PTCT · Life Sciences
The appointment of Jessica Chutter, a highly experienced biotech investment banker, to the board is a strategic positive for PTC Therapeutics. Her extensive background in capital raising and strategic transactions at Morgan Stanley will be invaluable as the company navigates its next phase of growth, following a significant financial turnaround in the previous year. This move strengthens the board's expertise in financial strategy and corporate development.
At the time of this filing, PTCT was trading at $64.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.3B. The 52-week trading range was $35.95 to $87.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.